Related references
Note: Only part of the references are listed.Immune checkpoint inhibitors: new strategies to checkmate cancer
R. A. M. Wilson et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2018)
CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8(+) T Cells
Fernando P. Canale et al.
CANCER RESEARCH (2018)
The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets
Bertrand Allard et al.
IMMUNOLOGICAL REVIEWS (2017)
Targeting A2 adenosine receptors in cancer
David Allard et al.
IMMUNOLOGY AND CELL BIOLOGY (2017)
Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy
Paul A. Beavis et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Antigen spread (AgS) after sipuleucel-T (sip-T): A cross-trial comparison of 4 sip-T clinical trials of patients (pts) with prostate cancer (PC).
Lawrence Fong et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
Silvana Morello et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2017)
Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease
Fabrizio Stocchi et al.
NEUROLOGY (2017)
CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF--mTOR-HIF-1 signaling in patients with non-small cell lung cancer
Jieyao Li et al.
ONCOIMMUNOLOGY (2017)
CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer
Bruno G. Leclerc et al.
CLINICAL CANCER RESEARCH (2016)
Loss of CD73-mediated actin polymerization promotes endometrial tumor progression
Jessica L. Bowser et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Overexpression of CD39 in hepatocellular carcinoma is an independent indicator of poor outcome after radical resection
Xiao-Yan Cai et al.
MEDICINE (2016)
High expression of CD39 in gastric cancer reduces patient outcome following radical resection
Xiao-Yan Cai et al.
ONCOLOGY LETTERS (2016)
A Metabolic immune Checkpoint: Adenosine in Tumor Microenvironment
Akio Ohta
FRONTIERS IN IMMUNOLOGY (2016)
CD73-adenosine reduces immune responses and survival in ovarian cancer patients
Pierre-Olivier Gaudreau et al.
ONCOIMMUNOLOGY (2016)
Targeting CD73 in the tumor microenvironment with MEDI9447
Carl M. Hay et al.
ONCOIMMUNOLOGY (2016)
Purinergic regulation of the immune system
Caglar Cekic et al.
NATURE REVIEWS IMMUNOLOGY (2016)
Something in the Air: Hyperoxic Conditioning of the Tumor Microenvironment for Enhanced Immunotherapy
Robert D. Leone et al.
CANCER CELL (2015)
CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer
Marian S. Wettstein et al.
DISEASE MARKERS (2015)
The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment
Gregory K. Pennock et al.
ONCOLOGIST (2015)
Allosteric interactions between agonists and antagonists within the adenosine A2A receptor-dopamine D2 receptor heterotetramer
Jordi Bonaventura et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Immunological mechanisms of the antitumor effects of supplemental oxygenation
Stephen M. Hatfield et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
CD39: A complementary target to immune checkpoints to counteract tumor-mediated immunosuppression
Nathalie Bonnefoy et al.
ONCOIMMUNOLOGY (2015)
Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance)
Stephanie M. Cushman et al.
CLINICAL CANCER RESEARCH (2015)
Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity
Jeremy Bastid et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Adenosine A2A Receptors Intrinsically Regulate CD8+ T Cells in the Tumor Microenvironment
Caglar Cekic et al.
CANCER RESEARCH (2014)
Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor
Deepak Mittal et al.
CANCER RESEARCH (2014)
Adenosine A2A Receptor Antagonists in Parkinson's Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued
Annalisa Pinna
CNS DRUGS (2014)
Targeting Cancer-Derived Adenosine: New Therapeutic Approaches
Arabella Young et al.
CANCER DISCOVERY (2014)
Hostile, Hypoxia-A2-Adenosinergic Tumor Biology as the Next Barrier to Overcome for Tumor Immunologists
Michail V. Sitkovsky et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Immunogenic Cell Death in Cancer Therapy
Guido Kroemer et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer in Cd39/Entpd1 null Mice
Xiaofeng Sun et al.
HEPATOLOGY (2013)
Extracellular adenosine regulates naive T cell development and peripheral maintenance
Caglar Cekic et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Anti-Human CD73 Monoclonal Antibody Inhibits Metastasis Formation in Human Breast Cancer by Inducing Clustering and Internalization of CD73 Expressed on the Surface of Cancer Cells
Mikkel G. Terp et al.
JOURNAL OF IMMUNOLOGY (2013)
IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39
Ivan D. Mascanfroni et al.
NATURE IMMUNOLOGY (2013)
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer
Sherene Loi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors
Paul A. Beavis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Expression and clinical significance of CD73 and hypoxia-inducible factor-1α in gastric carcinoma
Xiao-Xia Lu et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2013)
Increased CD39 expression on CD4+ T lymphocytes has clinical and prognostic significance in chronic lymphocytic leukemia
Chava Perry et al.
ANNALS OF HEMATOLOGY (2012)
Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor
Adam T. Waickman et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
CD73-Deficient Mice Are Resistant to Carcinogenesis
John Stagg et al.
CANCER RESEARCH (2012)
High expression of CD73 as a poor prognostic biomarker in human colorectal cancer
Xian-Rui Wu et al.
JOURNAL OF SURGICAL ONCOLOGY (2012)
CD73 Expression as a Potential Marker of Good Prognosis in Breast Carcinoma
Anna Supernat et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2012)
CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis
John Stagg et al.
CANCER RESEARCH (2011)
CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice
Long Wang et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer
Beat M. Kuenzli et al.
PURINERGIC SIGNALLING (2011)
CD39/ENTPD1 Expression by CD4+Foxp3+ Regulatory T Cells Promotes Hepatic Metastatic Tumor Growth in Mice
Xiaofeng Sun et al.
GASTROENTEROLOGY (2010)
Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial
H. H. Fernandez et al.
PARKINSONISM & RELATED DISORDERS (2010)
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis
John Stagg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Adenosine regulates CD8 T-cell priming by inhibition of membrane-proximal T-cell receptor signalling
Carsten Linnemann et al.
IMMUNOLOGY (2009)
Human Follicular Lymphoma CD39+-Infiltrating T Cells Contribute to Adenosine-Mediated T Cell Hyporesponsiveness
Shannon P. Hilchey et al.
JOURNAL OF IMMUNOLOGY (2009)
Adenosine receptors in regulation of dendritic cell differentiation and function
Sergey V. Novitskiy et al.
BLOOD (2008)
Disordered purinergic signaling inhibits pathological angiogenesis in Cd39/Entpd1-null mice
Shaun W. Jackson et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression
Silvia Deaglio et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Upregulation of CD39/NTPDases and P2 receptors in human pancreatic disease
Beat M. Kuenzli et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2007)
A2A adenosine receptor protects tumors from antitumor T cells
Akio Ohta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Adenosine inhibits activation-induced T cell expression of CD2 and CD28 co-stimulatory molecules: Role of interleukin-2 and cyclic AMP signaling pathways
JJ Butler et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2003)
Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage
A Ohta et al.
NATURE (2001)
Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell receptor
T Vang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Share Paper
